Kinarus Therapeutics Holding AG / Key word(s): Study results Kinarus Therapeutics Announces Discontinuation of the Phase 2 KINETIC Study of KIN001 in Hospitalized COVID-19 Patients Following a Prespecified
Kinarus Therapeutics Holding AG / Key word(s): Half Year Results Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update 31-Aug-2022 / 07:00 CET/CEST Release of an ad
Kinarus Therapeutics Holding AG / Key word(s): Miscellaneous Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19 22-Aug-2022 / 07:06 CET/CEST Release of an ad hoc announcement
KIN001 has synergistic antiviral, anti-inflammatory activity, and anti-fibrotic mechanismsPhase 2 trials of KIN001 in hospitalized and ambulatory COVID-19 patients ongoingInterim data from Phase 2 study
Kinarus Therapeutics Holding AG / Key word(s): Miscellaneous Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville 22-Aug-2022 / 07:00 CET/CEST Release
Kinarus Therapeutics Holding AG / Key word(s): Miscellaneous Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville 22-Aug-2022 / 07:00 CET/CEST Release
Financing to be drawn in tranchesFinancing will enable Kinarus to advance the clinical development of KIN001 Basel, Switzerland, August 22, 2022. Kinarus Therapeutics Holding AG (SIX: KNRS) ("Kinarus")
Kinarus Therapeutics Holding AG / Key word(s): Conference/Research Update Kinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related Macular Degeneration and
Kinarus Therapeutics Holding AG (SIX: KNRS) ("Kinarus"), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of viral, respiratory